

Advanced understanding of the tumor microenvironment with multiplex analysis. An automated 7-color multiplex assay using Akoya's Opal Technology

Imaging

Bhavika Patel, PhD. (bpatel@lanternedx.com), LanterneDx, **Stephanie Allen**, LanterneDx, **Najiba Mammadova, PhD**, Akoya Biosciences, **Agnes Haggerty, PhD**, Akoya Biosciences, **Navi Mehra, PhD**, LanterneDx

"Immunotherapy and precision medicine are rapidly developing approaches to cancer therapy. Biomarkers that detect the tumor and tumor microenvironment allow for the development of strategies that accelerate the expansion of treatments to enhance a patient's immune system. Akoya's MOTiF™ PD-1/PD-L1 Panel is a validated, multiplex immunoassay enabling detection of the 6 most clinically relevant immuno-oncology targets: PD-1, PD-L1, FoxP3, CD8, CD68, and PanCK. This panel provides unparalleled quantitative data for pre-clinical and translational Immuno-Oncology research.

The MOTiF™ PD-1/PD-L1 Panel was used to analyze the tumor microenvironment and specifically assess immune phenotypes of three different types of cancers: non-small cell lung cancer (NSCLC), lung adenocarcinoma, and large cell lung carcinoma (LCLC). In this study, we also demonstrate the utility of Akoya's MOTiF™ PD-1/PD-L1 panel kit in studying the cellular diversity of breast, colon, and head & neck cancer while retaining spatial context. These data provide insight into the innate and adaptive immune microenvironment for targeted design of new immunotherapies. "